Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR1D | P28221 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR1E | P28566 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850214 | 1.00 | KDM4E (0.70) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL876693 | 1.00 | KDM4E (0.70) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL4120269 | 1.00 | KDM4E (0.70) | KDM4EMAPTMEN1LMNAMPO | |
| Hydrochloric Acid SCHEMBL27780592 | 0.99 | KDM4E (0.68) | KDM4EMAPTMEN1LMNAMPO | |
| Hydrochloric Acid SCHEMBL8398299 | 0.99 | KDM4E (0.68) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL1069904 | 0.87 | KDM4E (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL27640891 | 0.87 | KDM4E (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL2250396 | 0.87 | MAPT (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL2250392 | 0.87 | MAPT (0.72) | KDM4EMAPTMEN1LMNAMPO | |
| SCHEMBL9609465 | 0.86 | MEN1 (0.71) | KDM4EMAPTMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101654426-B | Method for preparing ilomastat | INST PHARM & TOXICOLOGY AMMS | 2013-04-17 | — | — | CN | claimed |
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | claimed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | claimed |
| CN-101654426-A | Method for preparing ilomastat | POISON MED INST PLA MED ACAD | 2010-02-24 | — | — | CN | claimed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | claimed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-5892112-A | ACYLATION OF AMINO ACIDS WITH ANHYDRIDES OR CARBOXY GROUPS, AMIDATION WITH AMINE AND CONVERSION OF ACID OR ESTER TO HYDROXAMIC ACID AND HYDROLYSIS | GLYCOMED INCORPORATED (US) | 1999-04-06 | — | — | US | claimed |
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (MA) | 2024-08-06 | — | — | US | disclosed |
| WO-2024147125-A1 | CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-11 | — | — | WO | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-5109000-A | THIOL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS COLLAGENASE INHIBITOR | BEECHAM GROUP P.L.C. (GB) | 1992-04-28 | — | — | US | disclosed |
| EP-0273689-B1 | DERIVATIVES OF N-(2-ALKYL-3-MERCAPTO-GLUTARYL) ALPHA-AMINO ACIDS AND THEIR USE AS COLLAGENASE INHIBITORS | BEECHAM GROUP PLC (GB) | 1991-11-27 | — | — | EP | disclosed |
| US-4937243-A | TREATING CONNECTIVE TISSUE DISEASES | BEECHAM GROUP P.L.C. (GB) | 1990-06-26 | — | — | US | disclosed |
| US-4935404-A | ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES | BEECHAM GROUP P.L.C. OF BEECHAM HOUSE (GB) | 1990-06-19 | — | — | US | disclosed |
| EP-0320118-A2 | Peptides with collagenase inhibiting activity | BEECHAM GROUP PLC (GB) | 1989-06-14 | — | — | EP | disclosed |
| EP-0273689-A2 | Derivatives of N-(2-alkyl-3-mercapto-glutaryl) alpha-amino acids and their use as collagenase inhibitors | BEECHAM GROUP PLC (GB) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | TFAM, HSPE1, PRDX3 | KDM4E 1642/4885MAPT 577/4885MEN1 153/4885 |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | KDM4E 1766/4885MAPT 2505/4885MEN1 741/4885 |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK2AP2 | KDM4E 2512/4885MAPT 3481/4885MEN1 3029/4885 |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | KDM4E 3895/4885MAPT 192/4885MEN1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.